Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability
Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P< .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.
Authors
- Natalie Danziger (ORCID: https://orcid.org/0000-0003-2642-7160)
- Sabarinath Venniyil Radhakrishnan (ORCID: https://orcid.org/0000-0003-3277-4169)
- Ravi Kishore Narra (ORCID: https://orcid.org/0000-0002-1675-8479)
- Othman Salim Akhtar (ORCID: https://orcid.org/0000-0003-1673-9670)
- Anita D’Souza (ORCID: https://orcid.org/0000-0002-1092-5643)
- Douglas I. Lin (ORCID: https://orcid.org/0000-0003-0105-9760)
- Meera Mohan (ORCID: https://orcid.org/0000-0002-6913-6526)
- Binod Dhakal (ORCID: https://orcid.org/0000-0002-4377-9742)
- Caleb Ho (ORCID: https://orcid.org/0000-0001-5448-4635)
- Marcelo C. Pasquini (ORCID: https://orcid.org/0000-0003-1579-2293)
- Razelle Kurzrock
Institutions
- Medical College of Wisconsin (US)
- Boston Foundation (US)
- GlobalFoundries (United States) (US)
Publication Details
- Journal
- Blood Advances
- Published
- 2025-12-18
- DOI
- https://doi.org/10.1182/bloodadvances.2025018342
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Celgene
- Janssen Scientific Affairs
- Incyte
- Grifols
- Genentech
- Foundation Medicine
- Legend Biotech
- National Cancer Institute